WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2004030685) USE OF IL-2 RECEPTOR ANTIBODIES TO PREVENT TOXICITY ASSOCIATED WITH AMPHOTERICIN B ANTIMYCOTIC THERAPY
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2004/030685    International Application No.:    PCT/EP2003/010888
Publication Date: 15.04.2004 International Filing Date: 01.10.2003
Chapter 2 Demand Filed:    25.03.2004    
IPC:
A61K 31/7048 (2006.01), A61K 39/395 (2006.01)
Applicants: F. HOFFMANN-LA ROCHE AG [CH/CH]; 124, Grenzacherstrasse, CH-4070 Basle (CH).
THE UNIVERSITY OF MISSISSIPPI [US/US]; 125 Old Chemistry, University, MS 38677 (US).
THE UNIVERSITY OF MISSISSIPPI MEDICAL CENTER [US/US]; Medical Center, 2500 North State Street, Jackson, MS 39216-4505 (US)
Inventors: CHAPMAN, Stanley, Willetts; (US).
CLEARY, John, D.; (US).
GORDON, Robert, D.; (US)
Agent: HEIROTH, Ulrike; Grenzacherstrasse 124, CH-4070 Basel (CH)
Priority Data:
60/416,302 04.10.2002 US
Title (EN) USE OF IL-2 RECEPTOR ANTIBODIES TO PREVENT TOXICITY ASSOCIATED WITH AMPHOTERICIN B ANTIMYCOTIC THERAPY
(FR) UTILISATION D'ANTICORPS DU RECEPTEUR DE L'INTERLEUKINE 2
Abstract: front page image
(EN)This invention relates to a method for treating a patient having a fungal infection. The invention comprises administering to the patient a therapeutically effective amount of a polyene antifungal (e.g., amphotericin B) in association with a therapeutically effective amount of a interleukin-2 inhibitor (e.g., chimeric or humanized monoclonal antibody that binds to the p55 subunit of the human interleukin-2 receptor and inhibits binding of interleukin-2 to an interleukin-2 receptor).
(FR)Cette invention a trait à une méthode de traitement d'un patient atteint d'infection fongique. La méthode consiste à administrer à ce patient une quantité efficace du point de vue thérapeutique d'un antifongique polyène (par exemple, de l'amphotéricine B) associé à une quantité efficace du point de vue thérapeutique d'un inhibiteur de l'interleukine 2 (par exemple un anticorps monoclonal chimérique ou humanisé, se fixant à la sous-unité p55 du récepteur de l'interleukine 2 et inhibant la fixation de l'interleukine 2 à un récepteur de cette même interleukine 2).
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW.
African Regional Intellectual Property Organization (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)